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The anticancer potential of catechins derived from green tea is not well understood, in part because
catechin-related growth suppression and/or apoptosis appears to vary with the type and stage of malig-
nancy as well as with the type of catechin. This in vitro study examined the biological effects of epicat-
echin (EC), epigallocatechin (EGC), EC 3-gallate (ECG) and EGC 3-gallate (EGCG) in cell lines from
human gender-specific cancers. Cell lines developed from organ-confined (HH870) and metastatic
(DU145) prostate cancer, and from moderately (HH450) and poorly differentiated (HH639) epithelial
ovarian cancer were grown with or without EC, EGC, ECG or EGCG. When untreated cells reached
confluency, viability and doubling time were measured for treated and untreated cells. Whereas EC
treatment reduced proliferation of HH639 cells by 50%, EGCG suppressed proliferation of all cell
lines by 50%. ECG was even more potent: it inhibited DU145, HH870, HH450 and HH639 cells at
concentrations of 24, 27, 29 and 30 mM, whereas EGCG inhibited DU145, HH870, HH450 and
HH639 cells at concentrations 89, 45, 62 and 42 mM. When compared with EGCG, ECG more effect-
ively suppresses the growth of prostate cancer and epithelial ovarian cancer cell lines derived from
tumors of patients with different stages of disease.
Keywords: Green tea – epicatechin (EC) – epigallocatechin (EGC) – EC 3-gallate (ECG) – EGC
3-gallate (EGCG) – organ-confined – metastatic – prostate cancer – epithelial ovarian cancer –
viability – doubling time – 50% inhibitory concentration (IC50)
Introduction
There is accruing evidence that green tea may have anticancer
activity (1), but the mechanisms for this action are poorly
understood. Green tea is produced from the shrub Camellia
sinensis (Fig. 1); leaves are dried but not fermented so that
the green coloration attributed to polyphenols is retained.
Commercially prepared green tea extracts contain  60%
polyphenols (1). These polyphenols are the source of bio-
flavonoids, which have strong antioxidant activity.
The major bioflavonoids in green tea are epicatechins. Like
all bioflavonoids, the tea catechins have three hydrocarbon
rings; hydroxyl molecules are found at the 3, 5, and 7 positions
(Fig. 2). The four major tea catechins are epicatechin (EC),
EC 3-gallate (ECG), epigallocatechin (EGC) and EGC
3-gallate (EGCG). The relative proportions of EC, ECG,
EGC and EGCG in non-decaffeinated green tea are 792 ± 3,
1702 ± 16, 1695 ± 1 and 8295 ± 92 mg 100 g
 1 dry wt,
respectively; corresponding proportions in non-decaffeinated
black tea are 240 ± 1, 761 ± 4, 1116 ± 24 and 1199 ±
0.12 mg 100 g
 1 dry wt (1).
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they reportedly may promote apoptosis (2–6), arrest metastasis
by inhibiting metalloproteinases (7,8), impair angiogenesis
(9,10) and reverse multidrug resistance (11,12). Although
all epicatechins except EC can potentially suppress cell
proliferation (13–18), EGCG appears the most promising and
is therefore under clinical investigation in chemoprevention
trials (19). However, given the wide range in physiologic
potency of the different catechins, an exclusive focus on
EGCG is probably short-sighted. EGCG is reportedly more
effective than EGC in decreasing the intestinal absorption of
cholesterol (20) and it is the most potent catechin inhibitor of
HIV-1 reverse transcriptase (21), but ECG has the strongest
collagenase inhibitory effect (22) and the highest antioxidant
potential (23). By contrast, only EGC is a potent mediator of
oxidative modification and an inhibitor of xanthine oxidase
during hepatic catabolism of purines (24).
We hypothesized that the in vitro anticancer action of the
various catechins varies with the type and stage of malignancy.
We tested this hypothesis by examining proliferation of
catechin-treated cell lines derived from organ-confined or
metastatic prostate cancer (CaP) and from moderately or
poorly differentiated epithelial ovarian cancer (EOC). The
goal was to obtain data that would be useful for developing
chemopreventive and therapeutic clinical trials in patients
with gender-specific and non-specific solid tumors.
Materials and Methods
Human Cancer Cell Lines
Four gender-specific human cancer cell lines were used. The
HH870 androgen-receptor-negative CaP cell line was devel-
oped at Hoag Cancer Center, Newport Beach, CA, from an
organ-confined primary tumor that had been resected from
a 56-year-old, previously untreated Caucasian (25). This
tumor was Gleason Grade 3/4, with no evidence of vascular
or perineural invasion or extracapsular extension (stage T2b).
The DU145 metastatic CaP cell line (American Type Culture
Collection line HTB-81) was derived from a brain lesion of
69-year-old male Caucasian. It is androgen insensitive and
does not express prostate-specific antigen. Two EOC cell
lines developed at Hoag Cancer Center were also used:
HH639 was from a poorly differentiated clear cell,
Grade 3 carcinoma in the omentum and left ovary of a 56-
year-old Caucasian female; HH450 was from moderately dif-
ferentiated metastatic cells recovered from the abdominal fluid
of a 52-year-old Asian female.
All four cell lines were cryopreserved in liquid nitrogen free-
zer at  70
oC. For recovery of cryopreserved cells, the vials
were transferred to a 37
oC water bath for 15–30 s, further
thawed at room temperature and then transferred to a 15 ml
polypropylene tube with a Pasteur pipette. An aliquot of 9 ml
of RPMI-9% fetal bovine serum (FBS) was added in drops.
The cells were allowed to settle for 5 min and then centrifuged
at 4
oC for 10 min at 300 g. Supernatant was removed, and cells
were suspended in fresh RPMI, gently tapped and
vortexed. Cell viability was monitored by 0.2% trypan blue
dye exclusion, and cell count was determined using a
hemocytometer.
Figure 1. Morphology of Green Tea, Camellia sinensis.
Figure 2. Structure of epicatechin (EC), epigallocatechin (EGC), epicatechin
gallate (ECG) and epigallocatechin gallate (EGCG) used in this investigation.
All bioflavanoids have three rings; tea catechins are flavan-3-ols with an
hydroxyl group at the 3, 5 and 7 positions.
238 Tea epicatechins suppress growth of human cancerCells recovered from cryovials were grown in RPMI-1640
with glutamine (Invitrogen, Carlsbad, CA) supplemented
with 9% FBS, HEPES buffer, gentamycin (5 mg%) and fungi-
zone (0.5 mg%), at 37 C in a humidified atmosphere of 5%
CO2. Upon confluency, cells were detached with sterile
EDTA-dextrose (137 mM sodium chloride, 5.4 mM potassium
chloride, 5.6 mM dextrose, 0.54 mM ethylene diamine tetra
acetate (EDTA), 7.1 mM sodium bicarbonate) at 37 C for
5–15 min (or  45 min for HH639), recovered with cold
RPMI-1640-9% FBS and resuspended in the same medium.
Use of trypsin was avoided for harvesting the cells. Cell
viability and cell count were reassessed before cells were
seeded in culture flasks.
Tea Epicatechins
All epicatechins used in this study (Fig. 2) were obtained from
Sigma (EC, Sigma E4018; FW 290.3; ECG , Sigma E3892,
FW 442.4; EGC, Sigma E3768, FW 306.3; EGC, Sigma
E4143, FW 458.4) and were 98% pure as assessed by high-
performance liquid chromatography (by the commercial
source). Stock solutions were prepared under sterile conditions
Figure 3. Photomicrographs of cells grown in culture with 0, 25, 50, 75 or 100 mM of ECG or EGCG. Organ-confined prostate cancer cell line HH870 and primary
and metastatic epithelial ovarian cancer cell lines (HH450 and HH639) were seeded (2.5 · 10
5 cells per line) into flasks containing culture medium (RPMI-1640
with 9% FBS-antibiotics) with or without ECG or EGCG. When growth of untreated (control) cells reached confluency, cell monolayers in each flask were pho-
tographed under a light microscope. Both ECG and EGCG significantly affected the density of each cell line. Decrease in cell density was observed at higher con-
centrations of ECG and EGCG. Magnification: ·100.
eCAM 2006;3(2) 239with 50, 60 or 100 mM of each epicatechin or with no epicat-
echin (control) in RPMI-1640 with glutamine (Invitrogen),
9% FBS, 0.54% HEPES buffer, gentamycin (5 mg%) and
fungizone (0.5 mg%).
Growth Conditions
All experiments used 25 ml sterile polystyrene tissue culture
flasks with a vented blue plug seal cap (Beckton Dickinson,
Franklin Lakes, NJ, Cat. No. 353107). Each flask contained
stock solution with or without epicatechin in concentrations
of 50 mM (five flasks for each epicatechin and five flasks for
control) and 25, 75 and 100 mM (three flasks for each epicat-
echin and three flasksfor control).Cells (0.25 · 10
6)s u s p e n d e d
in 10 ml of the RPMI-1640-FBS solution described above were
transferred to each flask and allowed to grow until control cells
reached confluency. The cells were detached with sterile
EDTA-dextrose at 37 C for 5 min, recovered with cold RPMI-
1640-FBS medium and resuspended in the same medium.
Cells were counted using a hemocytometer; trypan blue dye
exclusion was used to determine the number of viable versus
dead cells. The interval between seeding and confluent growth
of control cells was used to calculate the doubling time and the
number of cell cycles. The 50% inhibitory concentration (IC50)
of each catechin in each cell line was calculated using a software
program (Microcal Origin Corp, OriginLab Corporation, North-
ampton, MA). The cells were photographed directly from the
flask using light microscopy (Olympus IX-70, Japan).
Statistics
Analyses of variance and Fisher’s least significant difference
(LSD) method were used for pairwise comparisons of values
significant at the 0.05 level.
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Figure 4. Density of cancer cells seeded (2.5 · 10
5 cells per line) into flasks containing culture medium (RPMI-1640 with 9% FBS-antibiotics) with or without
catechins (50 mM) (n ¼ 5 per treatment). When growth of untreated cells reached confluency, cells from each flask were harvested and viable/dead cells were
counted. Mean and standard deviation are represented. P-values obtained with pairwise comparison and ANOVA are shown.
240 Tea epicatechins suppress growth of human cancerResults
ECG as a Better Growth Suppressor Than EGCG:
Microscopic Observations
Organ-confined prostate cancer cell line HH870 and primary
and metastatic epithelial ovarian cancer cell lines (HH450
and HH639) seeded (2.5 · 10
5 cells) in flasks with or without
various concentrations (25, 50, 75 or 100 mM) of ECG or
EGCG were photographed under a light microscope after the
untreated control cells reached confluency (Fig. 3). Both
ECG and EGCG significantly affected the density of each
cell line at or above 75 mM. The decrease in cell density at
higher concentrations is much pronounced for ECG than for
EGCG, a finding significant considering recommendations of
clinical trials with EGCG (19).
ECG Suppresses Viable Cell Density
Better Than EGCG
The mean density or viable cell number (in millions) (n ¼5 per
treatment) of different cell lines was examined with or without
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Figure 5. Doubling time of cancer cells seeded (0.25 · 10
6 per line) into flasks containing culture medium (RPMI-1640 with 9% FBS-antibiotics) with or without
catechins (50 mM) (n ¼ 5 per treatment). When untreated cells reached confluency, cells from each flask were harvested and viable/dead cells were counted.
Vertical bars refer to standard deviation. The mean doubling time was calculated from the mean of five viable cell counts. P-values were obtained with pairwise
comparison and ANOVA.
eCAM 2006;3(2) 241catechins (50 mM) (Fig. 4). The cell density was measured
when growth of untreated cells reached confluency. Statistical
analysis by ANOVA as well as by pairwise comparison
showed that both ECG and EGCG significantly affected the
cell density. ECG decreased the cell density of prostate cancer
cells DU145, HH870 and ovarian cancer cell line HH639 more
potently than EGCG. But EGCG inhibited the growth of
ovarian cancer cell line HH450 better than ECG, suggesting
the need to determine relative efficacy of ECG and EGCG in
clinical trials for different cancers.
Tumor Cell Doubling Time: ECG versus EGCG
Figure 5 shows the influence of the four epicatechins on cell
doubling time. ECG and/or EGCG prolonged the doubling
Table 1. Four different epicatechins (50 mM) on cell number, cell cycles and mean doubling time of prostate and epithelial ovarian cancer cell lines
Parameters Control EC ECG EGC EGCG
Organ-confined prostate cancer (HH870), 186 h* for confluent growth of untreated cells
Number of flasks 5 5 5 5 5
Initial seeding 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6
Cell number
† 1.39 · 10
6 1.22 · 10
6 0.54 · 10
6 1.19 · 10
6 0.76 · 10
6
Fold increase (approx.) >2 >2 1 >2 >1
Number of cell cycles 2.5 2 1 2 1.5
Dead cell count 0.22 · 10
6 0.12 · 10
6 0.1 · 10
6 0.2 · 10
6 0.16 · 10
6
Mean doubling time 76 h 82 h 195 h 83 h 147 h
Metastatic prostate cancer (DU145), 125 h* for confluent growth of untreated cells
Number of flasks 5 5 5 5 5
Initial seeding 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6
Cell number
† 1.56 · 10
6 1.11 · 10
6 0.64 · 10
6 1.31 · 10
6 0.74 · 10
6
Fold increase (approx.) >2  2 >1 >2 >1
Number of cell cycles 2.5 2 1.3 2.4 1.6
Dead cell count 0.45 · 10
6 0.3 · 10
6 0.24 · 10
6 0.34 · 10
6 0
Mean doubling time 51 h 60 h 96 h 53 h 81 h
Epithelial ovarian cancer (HH450), 219 h* for confluent growth of untreated cells
Number of flasks 5 5 5 5 5
Initial seeding 0.16 · 10
6 0.16 · 10
6 0.16 · 10
6 0.16 · 10
6 0.16 · 10
6
Cell number
† 0.93 · 10
6 1.06 · 10
6 0.66 · 10
6 1.06 · 10
6 0.48 · 10
6
Fold increase (approx.) >3 >33 >3 >2
Number of cell cycles 2.5 2.7 1.9 2.7 1.5
Dead cell count 0.66 · 10
6 0.40 · 10
6 0.29 · 10
6 0.46 · 10
6 0.14 · 10
6
Mean doubling time 90 h 82 h 130 h 83 h 106 h
Epithelial ovarian cancer (HH639), 170 h
z for confluent growth of untreated cells
Number of flasks 5 5 5 5 5
Initial seeding 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6 0.25 · 10
6
Cell number
† 2.1 · 10
6 0.90 · 10
6 0.20 · 10
6* 1.83 · 10
6† 1.10 · 10
6
Fold increase (approx.) 3  3 0 32
Number of cell cycles 3  2 0 32
Dead cell count 0.27 · 10
6 0.16 · 10
6 0.11 · 10
6 0.014 · 10
6 0.30 · 10
6
Mean doubling time 56 h 124 h 0 51 h 88 h
*Four flasks were counted;
†mean viable cell count;
zthree flasks were counted. Significant values are shown in bold.
Table 2. Relative inhibitory potency (IC50) of epicatechin gallate
(ECG) and epigallocatechin gallate (EGCG) on organ-confined (HH870)
and metastatic (DU145) prostate cancer and ovarian cancer (HH450 and
HH639)
Tumor cell line IC50 in mM
ECG EGCG
Prostate cancer
HH870 27.44 45.43
DU145 24.09 88.66
Epithelial ovarian cancer
HH450 28.95 62.25
HH639 29.59 42.21
242 Tea epicatechins suppress growth of human cancerFigure 6. Suppression of cell growth by ECG and EGCG. (A) DU145; (B) HH870; (C) HH450; (D) HH639. Cells (0.25 · 10
6 per line) were seeded in flasks
containing culture medium (RPMI-1640 with 9% FBS-antibiotics) with or without ECG or EGCG at concentrations of 0, 25, 50, 75 and 100 mM (three flasks
for each dose). Mean (circles) and standard deviation (vertical lines) are represented. When untreated cells reached confluency, cell monolayers in each
flask were photographed under a light microscope, harvested and counted. The suppressive effect on cell density was striking at higher concentrations of ECG
and EGCG. At 25 mM of EGCG, cell counts for HH870 and DU145 were significantly higher than control values. P-values indicate significant differences
between mean values of treated and untreated cells.
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n
M
D
A
-
M
B
-
2
3
1
c
e
l
l
s
.
I
n
t
h
i
s
c
e
l
l
l
i
n
e
,
E
G
C
G
(
2
5
m
M
)
p
r
o
d
u
c
e
d
a
g
r
e
a
t
e
r
C
T
X
e
f
f
e
c
t
t
h
a
n
4
-
O
H
T
(
1
m
M
)
.
T
h
e
c
o
m
b
i
n
a
t
i
o
n
o
f
t
h
e
t
w
o
r
e
s
u
l
t
e
d
i
n
s
y
n
e
r
g
i
s
t
i
c
C
T
X
C
o
l
o
n
H
T
-
2
9
E
G
C
G
V
a
l
c
i
c
e
t
a
l
.
(
1
3
)
G
C
,
E
C
,
E
G
C
,
E
C
G
a
n
d
E
G
C
G
e
x
t
r
a
c
t
e
d
f
r
o
m
g
r
e
e
n
t
e
a
l
e
a
v
e
s
a
n
d
c
a
t
e
c
h
i
n
(
C
)
w
e
r
e
t
e
s
t
e
d
a
g
a
i
n
s
t
H
T
-
2
9
c
o
l
o
n
c
a
n
c
e
r
c
e
l
l
l
i
n
e
.
O
f
a
l
l
t
h
e
c
a
t
e
c
h
i
n
s
,
E
G
C
G
w
a
s
t
h
e
m
o
s
t
p
o
t
e
n
t
i
n
h
i
b
i
t
o
r
o
f
g
r
o
w
t
h
C
o
l
o
n
H
T
-
2
9
E
G
C
G
J
u
n
g
e
t
a
l
.
(
9
)
E
G
C
G
,
t
h
e
m
o
s
t
a
b
u
n
d
a
n
t
c
a
t
e
c
h
i
n
i
n
g
r
e
e
n
t
e
a
e
x
t
r
a
c
t
,
i
n
h
i
b
i
t
e
d
E
r
k
-
1
a
n
d
E
r
k
-
2
a
c
t
i
v
a
t
i
o
n
i
n
s
e
r
u
m
-
d
e
p
r
i
v
e
d
H
T
-
2
9
h
u
m
a
n
c
o
l
o
n
c
a
n
c
e
r
c
e
l
l
s
i
n
v
i
t
r
o
i
n
a
d
o
s
e
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
.
E
G
C
,
E
C
G
a
n
d
E
C
d
i
d
n
o
t
a
f
f
e
c
t
E
r
k
-
1
o
r
2
a
c
t
i
v
a
t
i
o
n
a
t
a
c
o
n
c
e
n
t
r
a
t
i
o
n
o
f
3
0
m
M
.
E
G
C
G
a
l
s
o
i
n
h
i
b
i
t
e
d
t
h
e
i
n
c
r
e
a
s
e
o
f
V
E
G
F
e
x
p
r
e
s
s
i
o
n
a
n
d
p
r
o
m
o
t
e
r
a
c
t
i
v
i
t
y
i
n
d
u
c
e
d
b
y
s
e
r
u
m
s
t
a
r
v
a
t
i
o
n
.
I
n
v
i
v
o
,
i
n
a
t
h
y
m
i
c
B
A
L
B
/
c
n
u
d
e
m
i
c
e
i
n
o
c
u
l
a
t
e
d
s
u
b
c
u
t
a
n
e
o
u
s
l
y
w
i
t
h
H
T
-
2
9
c
e
l
l
s
w
e
r
e
t
r
e
a
t
e
d
w
i
t
h
d
a
i
l
y
i
n
t
r
a
p
e
r
i
t
o
n
e
a
l
i
n
j
e
c
t
i
o
n
s
o
f
E
C
(
n
e
g
a
t
i
v
e
c
o
n
t
r
o
l
)
o
r
E
G
C
G
a
t
1
.
5
m
g
d
a
y
(
-
1
)
m
o
u
s
e
(
-
1
)
s
t
a
r
t
i
n
g
2
d
a
y
s
a
f
t
e
r
t
u
m
o
r
c
e
l
l
i
n
o
c
u
l
a
t
i
o
n
.
T
r
e
a
t
m
e
n
t
w
i
t
h
E
G
C
G
i
n
h
i
b
i
t
e
d
t
u
m
o
r
g
r
o
w
t
h
(
5
8
%
)
,
m
i
c
r
o
v
e
s
s
e
l
d
e
n
s
i
t
y
(
3
0
%
)
,
a
n
d
t
u
m
o
r
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
(
2
7
%
)
a
n
d
i
n
c
r
e
a
s
e
d
t
u
m
o
r
c
e
l
l
a
p
o
p
t
o
s
i
s
(
1
.
9
-
f
o
l
d
)
a
n
d
e
n
d
o
t
h
e
l
i
a
l
c
e
l
l
a
p
o
p
t
o
s
i
s
(
3
-
f
o
l
d
)
r
e
l
a
t
i
v
e
t
o
t
h
e
c
o
n
t
r
o
l
c
o
n
d
i
t
i
o
n
(
P
<
0
.
0
5
f
o
r
a
l
l
c
o
m
p
a
r
i
s
o
n
s
)
G
a
s
t
r
i
c
M
K
-
1
E
G
C
G
K
i
n
j
o
e
t
a
l
.
(
6
)
A
m
o
n
g
t
h
e
s
i
x
a
c
t
i
v
e
f
l
a
v
a
n
-
3
-
o
l
s
,
E
C
,
E
G
C
,
E
G
C
G
,
G
C
,
E
C
G
,
G
C
G
,
E
G
C
G
a
n
d
G
C
G
s
h
o
w
e
d
t
h
e
h
i
g
h
e
s
t
a
n
t
i
p
r
o
l
i
f
e
r
a
t
i
v
e
a
c
t
i
v
i
t
y
a
g
a
i
n
s
t
h
u
m
a
n
s
t
o
m
a
c
h
c
a
n
c
e
r
(
M
K
-
1
)
c
e
l
l
s
.
T
h
e
s
e
d
a
t
a
s
u
g
g
e
s
t
t
h
a
t
t
h
e
p
r
e
s
e
n
c
e
o
f
t
h
e
t
h
r
e
e
a
d
j
a
c
e
n
t
h
y
d
r
o
x
y
l
g
r
o
u
p
s
(
p
y
r
o
g
a
l
l
o
l
o
r
g
a
l
l
o
y
l
g
r
o
u
p
)
i
n
t
h
e
m
o
l
e
c
u
l
e
w
o
u
l
d
b
e
a
k
e
y
f
a
c
t
o
r
f
o
r
e
n
h
a
n
c
i
n
g
t
h
e
a
c
t
i
v
i
t
y
.
S
i
n
c
e
r
e
a
c
t
i
v
e
o
x
y
g
e
n
s
p
e
c
i
e
s
p
l
a
y
a
n
i
m
p
o
r
t
a
n
t
r
o
l
e
i
n
c
e
l
l
d
e
a
t
h
i
n
d
u
c
t
i
o
n
,
r
a
d
i
c
a
l
s
c
a
v
e
n
g
i
n
g
a
c
t
i
v
i
t
y
w
a
s
e
v
a
l
u
a
t
e
d
u
s
i
n
g
t
h
e
D
P
P
H
(
1
,
1
-
d
i
p
h
e
n
y
l
-
2
-
p
i
c
r
y
l
h
y
d
r
a
z
y
l
)
r
a
d
i
c
a
l
.
T
h
e
o
r
d
e
r
o
f
s
c
a
v
e
n
g
i
n
g
a
c
t
i
v
i
t
y
w
a
s
E
C
G
 
E
G
C
G
 
E
G
C
 
G
C
 
E
C
.
T
h
e
c
o
m
p
o
u
n
d
s
h
a
v
i
n
g
a
g
a
l
l
o
y
l
m
o
i
e
t
y
s
h
o
w
e
d
m
o
r
e
p
o
t
e
n
t
a
c
t
i
v
i
t
y
.
T
h
e
c
o
n
t
r
i
b
u
t
i
o
n
o
f
t
h
e
p
y
r
o
g
a
l
l
o
l
m
o
i
e
t
y
i
n
t
h
e
B
-
r
i
n
g
t
o
t
h
e
s
c
a
v
e
n
g
i
n
g
a
c
t
i
v
i
t
y
s
e
e
m
e
d
t
o
b
e
l
e
s
s
t
h
a
n
t
h
a
t
o
f
t
h
e
g
a
l
l
o
y
l
m
o
i
e
t
y
M
e
l
a
n
o
m
a
U
A
C
C
-
3
7
5
E
G
C
G
V
a
l
c
i
c
e
t
a
l
.
(
1
3
)
G
C
,
E
C
,
E
G
C
,
E
C
G
a
n
d
E
G
C
G
e
x
t
r
a
c
t
e
d
f
r
o
m
g
r
e
e
n
t
e
a
l
e
a
v
e
s
a
n
d
c
a
t
e
c
h
i
n
(
C
)
w
e
r
e
t
e
s
t
e
d
a
g
a
i
n
s
t
U
A
C
C
-
3
7
5
m
e
l
a
n
o
m
a
c
e
l
l
l
i
n
e
.
O
f
a
l
l
t
h
e
g
r
e
e
n
t
e
a
c
o
m
p
o
n
e
n
t
s
,
E
G
C
G
w
a
s
t
h
e
m
o
s
t
p
o
t
e
n
t
i
n
h
i
b
i
t
o
r
o
f
g
r
o
w
t
h
G
l
i
o
b
l
a
s
t
o
m
a
A
1
7
2
E
G
C
G
¼
E
C
G
S
a
c
h
i
n
i
d
e
s
e
t
a
l
.
(
2
8
)
T
h
e
e
f
f
e
c
t
o
f
C
,
E
C
,
E
G
C
G
,
E
C
G
a
n
d
C
G
o
n
t
h
e
t
y
r
o
s
i
n
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
o
f
P
D
G
F
b
e
t
a
-
r
e
c
e
p
t
o
r
(
P
D
G
F
-
R
b
)
a
n
d
o
n
t
h
e
a
n
c
h
o
r
a
g
e
-
i
n
d
e
p
e
n
d
e
n
t
g
r
o
w
t
h
o
f
A
1
7
2
g
l
i
o
b
l
a
s
t
o
m
a
c
e
l
l
s
w
a
s
i
n
v
e
s
t
i
g
a
t
e
d
.
T
r
e
a
t
m
e
n
t
o
f
A
1
7
2
g
l
i
o
b
l
a
s
t
o
m
a
w
i
t
h
5
0
m
M
C
G
,
E
C
G
,
E
G
C
G
a
n
d
2
5
m
M
T
y
r
p
h
o
s
t
i
n
1
2
9
6
r
e
s
u
l
t
e
d
i
n
a
n
8
2
±
1
7
%
,
7
7
±
2
1
%
,
7
5
±
8
%
a
n
d
5
5
±
1
1
%
,
r
e
s
p
e
c
t
i
v
e
l
y
(
m
e
a
n
±
S
D
,
n
¼
3
)
i
n
h
i
b
i
t
i
o
n
o
f
t
h
e
P
D
G
F
-
B
B
-
i
n
d
u
c
e
d
t
y
r
o
s
i
n
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
o
f
P
D
G
F
-
R
b
.
T
h
e
P
D
G
F
-
R
b
d
o
w
n
s
t
r
e
a
m
i
n
t
r
a
c
e
l
l
u
l
a
r
t
r
a
n
s
d
u
c
t
i
o
n
p
a
t
h
w
a
y
i
n
c
l
u
d
i
n
g
t
y
r
o
s
i
n
e
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
o
f
p
h
o
s
p
h
o
l
i
p
a
s
e
C
-
g
1
(
P
L
C
-
g
1
)
a
n
d
p
h
o
s
p
h
a
t
i
d
y
l
i
n
o
s
i
t
o
l
3
0
-
k
i
n
a
s
e
(
P
I
3
0
-
K
)
w
a
s
a
l
s
o
i
n
h
i
b
i
t
e
d
.
S
p
h
e
r
o
i
d
f
o
r
m
a
t
i
o
n
w
a
s
c
o
m
p
l
e
t
e
l
y
i
n
h
i
b
i
t
e
d
b
y
5
0
m
M
E
C
G
,
C
G
,
E
G
C
G
a
n
d
b
y
2
5
m
M
T
y
r
p
h
o
s
t
i
n
1
2
9
6
.
T
h
e
c
a
t
e
c
h
i
n
s
p
o
s
s
e
s
s
i
n
g
t
h
e
g
a
l
l
a
t
e
g
r
o
u
p
a
c
t
a
s
a
n
t
i
c
a
n
c
e
r
a
g
e
n
t
s
p
r
o
b
a
b
l
y
p
a
r
t
l
y
v
i
a
t
h
e
i
r
a
b
i
l
i
t
y
t
o
s
u
p
p
r
e
s
s
t
h
e
t
y
r
o
s
i
n
e
k
i
n
a
s
e
a
c
t
i
v
i
t
y
o
f
t
h
e
P
D
G
F
-
R
b
L
u
n
g
P
C
-
9
E
G
C
G
¼
E
C
G
/
E
G
C
O
k
a
b
e
e
t
a
l
.
(
1
4
)
E
G
C
a
n
d
E
C
G
i
n
h
i
b
i
t
e
d
t
h
e
g
r
o
w
t
h
o
f
a
h
u
m
a
n
l
u
n
g
c
a
n
c
e
r
c
e
l
l
l
i
n
e
,
P
C
-
9
c
e
l
l
s
a
s
p
o
t
e
n
t
l
y
a
s
d
i
d
E
G
C
G
,
b
u
t
E
C
d
i
d
n
o
t
s
h
o
w
s
i
g
n
i
f
i
c
a
n
t
g
r
o
w
t
h
i
n
h
i
b
i
t
i
o
n
.
T
h
e
m
e
c
h
a
n
i
s
m
o
f
g
r
o
w
t
h
i
n
h
i
b
i
t
i
o
n
b
y
E
G
C
G
w
a
s
s
t
u
d
i
e
d
i
n
r
e
l
a
t
i
o
n
t
o
c
e
l
l
-
c
y
c
l
e
r
e
g
u
l
a
t
i
o
n
.
E
G
C
G
(
5
0
a
n
d
1
0
0
m
M
)
i
n
c
r
e
a
s
e
d
t
h
e
p
e
r
c
e
n
t
a
g
e
s
o
f
c
e
l
l
s
i
n
t
h
e
G
2
-
M
-
p
h
a
s
e
f
r
o
m
1
3
.
8
t
o
1
5
%
.
[
3
H
]
E
G
C
G
w
a
s
i
n
c
o
r
p
o
r
a
t
e
d
i
n
t
o
t
h
e
c
y
t
o
s
o
l
,
a
s
w
e
l
l
a
s
t
h
e
n
u
c
l
e
i
L
u
n
g
A
5
4
9
E
G
C
G
¼
E
C
G
F
u
j
i
m
o
t
o
e
t
a
l
.
(
1
6
)
E
G
C
G
o
r
E
C
G
a
n
d
g
e
n
i
s
t
e
i
n
a
s
a
c
o
n
t
r
o
l
d
o
s
e
d
e
p
e
n
d
e
n
t
l
y
i
n
h
i
b
i
t
e
d
t
h
e
g
r
o
w
t
h
o
f
h
u
m
a
n
l
u
n
g
c
a
n
c
e
r
c
e
l
l
l
i
n
e
,
A
5
4
9
c
e
l
l
s
,
s
t
r
o
n
g
l
y
e
l
e
v
a
t
e
d
h
n
R
N
P
B
1
p
r
o
t
e
i
n
a
n
d
i
n
c
r
e
a
s
e
d
G
2
/
M
-
p
h
a
s
e
c
e
l
l
s
a
s
s
o
c
i
a
t
e
d
w
i
t
h
i
n
d
u
c
t
i
o
n
o
f
a
p
o
p
t
o
t
i
c
c
e
l
l
s
.
T
r
e
a
t
m
e
n
t
o
f
A
5
4
9
c
e
l
l
s
w
i
t
h
E
G
C
G
,
E
C
G
o
r
g
e
n
i
s
t
e
i
n
s
i
g
n
i
f
i
c
a
n
t
l
y
i
n
h
i
b
i
t
e
d
t
h
e
e
x
p
r
e
s
s
i
o
n
l
e
v
e
l
s
o
f
h
n
R
N
P
B
1
m
R
N
A
a
n
d
t
h
e
e
l
e
v
a
t
e
d
l
e
v
e
l
s
o
f
h
n
R
N
P
B
1
p
r
o
t
e
i
n
,
b
o
t
h
o
f
w
h
i
c
h
a
r
e
c
o
n
s
t
i
t
u
t
i
v
e
l
y
e
l
e
v
a
t
e
d
i
n
c
a
n
c
e
r
c
e
l
l
s
.
F
u
r
t
h
e
r
m
o
r
e
,
b
o
t
h
E
G
C
G
a
n
d
g
e
n
i
s
t
e
i
n
i
n
h
i
b
i
t
e
d
t
h
e
p
r
o
m
o
t
e
r
a
c
t
i
v
i
t
y
o
f
h
n
R
N
P
A
2
/
B
1
g
e
n
e
e
x
p
r
e
s
s
i
o
n
,
w
i
t
h
I
C
5
0
v
a
l
u
e
s
2
9
m
M
f
o
r
E
G
C
G
a
n
d
6
6
m
M
f
o
r
g
e
n
i
s
t
e
i
n
,
s
u
g
g
e
s
t
i
n
g
t
h
e
i
n
t
e
r
a
c
t
i
o
n
o
f
E
G
C
G
o
r
g
e
n
i
s
t
e
i
n
w
i
t
h
t
h
e
t
r
a
n
s
c
r
i
p
t
i
o
n
a
l
c
o
m
p
l
e
x
P
a
n
c
r
e
a
t
i
c
H
P
A
C
E
G
C
G
¼
E
C
G
L
y
n
-
C
o
o
k
e
t
a
l
.
(
3
6
)
T
h
e
e
f
f
e
c
t
s
o
f
E
C
G
a
n
d
E
G
C
G
o
n
t
h
e
g
r
o
w
t
h
o
f
h
u
m
a
n
p
a
n
c
r
e
a
t
i
c
a
d
e
n
o
c
a
r
c
i
n
o
m
a
(
H
P
A
C
)
w
e
r
e
d
e
t
e
r
m
i
n
e
d
.
E
C
G
a
n
d
E
G
C
G
i
n
h
i
b
i
t
e
d
g
r
o
w
t
h
a
s
w
e
l
l
(
 
9
5
%
)
.
B
l
a
c
k
a
n
d
g
r
e
e
n
t
e
a
e
x
t
r
a
c
t
s
,
E
G
C
G
d
e
c
r
e
a
s
e
d
t
h
e
e
x
p
r
e
s
s
i
o
n
o
f
t
h
e
K
-
r
a
s
g
e
n
e
a
n
d
t
h
e
m
u
l
t
i
d
r
u
g
-
r
e
s
i
s
t
a
n
t
g
e
n
e
(
m
d
r
-
1
)
244 Tea epicatechins suppress growth of human cancerT
a
b
l
e
3
.
C
o
n
t
i
n
u
e
d
H
u
m
a
n
t
u
m
o
r
C
e
l
l
l
i
n
e
C
a
t
e
c
h
i
n
S
o
u
r
c
e
O
b
s
e
r
v
e
d
e
f
f
e
c
t
s
P
r
o
s
t
a
t
e
L
n
C
a
P
E
G
C
G
¼
E
C
G
L
y
n
-
C
o
o
k
e
t
a
l
.
(
3
6
)
E
C
G
a
n
d
E
G
C
G
s
i
g
n
i
f
i
c
a
n
t
l
y
i
n
h
i
b
i
t
e
d
g
r
o
w
t
h
o
f
p
r
o
s
t
a
t
e
t
u
m
o
r
(
L
N
C
a
P
)
a
n
d
i
n
c
r
e
a
s
e
d
e
x
p
r
e
s
s
i
o
n
o
f
t
h
e
m
d
r
-
1
g
e
n
e
i
n
L
N
C
a
P
O
r
a
l
s
q
u
a
m
o
u
s
S
C
C
-
2
5
E
G
C
G
¼
E
C
G
E
l
a
t
t
a
r
e
t
a
l
.
(
3
7
)
T
h
e
e
f
f
e
c
t
o
f
E
G
C
G
,
E
C
G
a
n
d
E
G
C
(
a
t
c
o
n
c
e
n
t
r
a
t
i
o
n
s
o
f
5
0
,
8
0
,
1
0
0
a
n
d
2
0
0
m
M
)
o
n
t
h
e
g
r
o
w
t
h
a
n
d
D
N
A
s
y
n
t
h
e
s
i
s
o
f
h
u
m
a
n
o
r
a
l
s
q
u
a
m
o
u
s
c
a
r
c
i
n
o
m
a
c
e
l
l
l
i
n
e
S
C
C
-
2
5
w
a
s
d
e
t
e
r
m
i
n
e
d
.
A
t
t
h
e
f
o
u
r
d
o
s
e
l
e
v
e
l
s
u
s
e
d
,
t
h
e
t
h
r
e
e
c
o
m
p
o
u
n
d
s
i
n
d
u
c
e
d
s
i
g
n
i
f
i
c
a
n
t
d
o
s
e
-
d
e
p
e
n
d
e
n
t
i
n
h
i
b
i
t
i
o
n
i
n
c
e
l
l
g
r
o
w
t
h
.
I
n
D
N
A
s
t
u
d
y
,
t
h
e
t
h
r
e
e
c
o
m
p
o
u
n
d
s
e
x
h
i
b
i
t
e
d
s
t
i
m
u
l
a
t
o
r
y
e
f
f
e
c
t
a
t
5
0
m
M
f
o
l
l
o
w
e
d
b
y
s
i
g
n
i
f
i
c
a
n
t
d
o
s
e
-
d
e
p
e
n
d
e
n
t
i
n
h
i
b
i
t
o
r
y
e
f
f
e
c
t
(
1
0
–
1
0
0
%
)
a
t
8
0
,
1
0
0
a
n
d
2
0
0
m
M
d
o
s
e
l
e
v
e
l
s
.
D
o
s
e
-
d
e
p
e
n
d
e
n
t
c
h
a
n
g
e
s
i
n
c
e
l
l
m
o
r
p
h
o
l
o
g
y
w
e
r
e
a
l
s
o
o
b
s
e
r
v
e
d
w
i
t
h
p
h
a
s
e
-
c
o
n
t
r
a
s
t
m
i
c
r
o
s
c
o
p
y
a
f
t
e
r
c
e
l
l
t
r
e
a
t
m
e
n
t
w
i
t
h
E
G
C
G
H
e
p
a
t
o
m
a
H
e
p
G
2
-
A
R
E
-
C
8
E
G
C
G
/
E
C
G
C
h
e
n
e
t
a
l
.
(
2
7
)
T
e
a
c
a
t
e
c
h
i
n
t
r
e
a
t
m
e
n
t
s
i
g
n
i
f
i
c
a
n
t
l
y
i
n
c
r
e
a
s
e
d
c
e
l
l
v
i
a
b
i
l
i
t
y
,
d
e
c
r
e
a
s
e
d
l
i
p
i
d
p
e
r
o
x
i
d
a
t
i
o
n
l
e
v
e
l
s
a
n
d
p
r
o
t
e
c
t
e
d
c
e
l
l
m
e
m
b
r
a
n
e
f
l
u
i
d
i
t
y
i
n
l
e
a
d
-
e
x
p
o
s
e
d
H
e
p
G
2
c
e
l
l
s
i
n
a
c
o
n
c
e
n
t
r
a
t
i
o
n
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
.
T
h
e
g
a
l
l
o
y
l
a
t
e
d
c
a
t
e
c
h
i
n
s
s
h
o
w
e
d
a
s
t
r
o
n
g
e
r
e
f
f
e
c
t
t
h
a
n
n
o
n
-
g
a
l
l
o
y
l
a
t
e
d
c
a
t
e
c
h
i
n
s
.
C
o
-
t
r
e
a
t
m
e
n
t
w
i
t
h
E
G
C
,
E
C
,
E
C
G
a
n
d
t
h
e
t
e
a
c
a
t
e
c
h
i
n
s
m
a
y
h
a
v
e
a
r
o
l
e
t
o
p
l
a
y
i
n
m
o
d
u
l
a
t
i
n
g
o
x
i
d
a
t
i
v
e
s
t
r
e
s
s
i
n
l
e
a
d
-
e
x
p
o
s
e
d
H
e
p
G
2
c
e
l
l
s
C
o
l
o
n
L
o
V
o
E
G
C
G
¼
E
G
C
T
a
n
e
t
a
l
.
(
3
8
)
T
r
e
a
t
m
e
n
t
o
f
L
o
V
o
c
o
l
o
n
c
a
n
c
e
r
c
e
l
l
s
w
i
t
h
E
G
C
G
a
n
d
E
G
C
r
e
s
u
l
t
e
d
i
n
t
h
e
g
r
o
w
t
h
s
u
p
p
r
e
s
s
i
o
n
a
n
d
i
n
d
u
c
t
i
o
n
o
f
a
p
o
p
t
o
s
i
s
i
n
a
t
i
m
e
-
a
n
d
c
o
n
c
e
n
t
r
a
t
i
o
n
-
d
e
p
e
n
d
e
n
t
m
a
n
n
e
r
.
E
C
G
a
n
d
E
C
,
h
o
w
e
v
e
r
,
d
i
d
n
o
t
h
a
v
e
t
h
e
s
a
m
e
e
f
f
e
c
t
s
.
I
n
a
d
d
i
t
i
o
n
,
t
r
e
a
t
m
e
n
t
w
i
t
h
E
G
C
G
,
E
G
C
a
n
d
E
C
G
c
a
u
s
e
d
L
o
V
o
c
e
l
l
s
a
r
r
e
s
t
a
t
G
1
-
p
h
a
s
e
i
n
t
h
e
c
e
l
l
-
c
y
c
l
e
p
r
o
g
r
e
s
s
i
o
n
,
w
h
e
r
e
a
s
E
C
r
e
s
u
l
t
e
d
i
n
a
n
a
r
r
e
s
t
a
t
S
-
p
h
a
s
e
O
r
a
l
s
q
u
a
m
o
u
s
H
S
C
-
2
E
C
G
B
a
b
i
c
h
e
t
a
l
.
(
1
8
)
T
h
e
r
e
l
a
t
i
v
e
c
y
t
o
t
o
x
i
c
i
t
y
(
C
T
X
)
o
f
E
C
G
t
o
c
a
r
c
i
n
o
m
a
H
S
C
-
2
c
e
l
l
s
a
n
d
n
o
r
m
a
l
H
G
F
-
2
f
i
b
r
o
b
l
a
s
t
s
c
e
l
l
s
f
r
o
m
t
h
e
h
u
m
a
n
o
r
a
l
c
a
v
i
t
y
,
a
s
c
o
m
p
a
r
e
d
w
i
t
h
o
t
h
e
r
p
o
l
y
p
h
e
n
o
l
s
i
n
t
e
a
,
w
a
s
e
v
a
l
u
a
t
e
d
.
F
o
r
t
h
e
H
S
C
-
2
c
a
r
c
i
n
o
m
a
c
e
l
l
s
,
E
C
G
,
C
G
a
n
d
E
G
C
G
g
r
o
u
p
e
d
a
s
h
i
g
h
l
y
t
o
x
i
c
,
E
G
C
a
s
m
o
d
e
r
a
t
e
l
y
t
o
x
i
c
,
a
n
d
C
a
n
d
E
C
a
s
l
e
a
s
t
t
o
x
i
c
.
F
o
r
t
h
e
H
G
F
-
2
f
i
b
r
o
b
l
a
s
t
s
,
E
C
G
a
n
d
C
G
g
r
o
u
p
e
d
a
s
h
i
g
h
l
y
t
o
x
i
c
,
E
G
C
G
a
s
m
o
d
e
r
a
t
e
l
y
t
o
x
i
c
,
a
n
d
E
G
C
,
C
a
n
d
E
C
a
s
l
e
a
s
t
t
o
x
i
c
.
T
h
e
C
T
X
e
f
f
e
c
t
s
o
f
t
h
e
p
o
l
y
p
h
e
n
o
l
s
w
e
r
e
m
o
r
e
p
r
o
n
o
u
n
c
e
d
t
o
t
h
e
c
a
r
c
i
n
o
m
a
,
t
h
a
n
t
o
t
h
e
n
o
r
m
a
l
,
c
e
l
l
s
.
T
h
e
a
d
d
i
t
i
o
n
o
f
E
C
G
t
o
c
e
l
l
c
u
l
t
u
r
e
m
e
d
i
u
m
l
e
d
t
o
t
h
e
g
e
n
e
r
a
t
i
o
n
o
f
h
y
d
r
o
g
e
n
p
e
r
o
x
i
d
e
(
H
2
O
2
)
.
B
u
t
E
C
G
,
a
s
c
o
m
p
a
r
e
d
w
i
t
h
E
G
C
G
,
w
a
s
a
p
o
o
r
g
e
n
e
r
a
t
o
r
o
f
H
2
O
2
a
n
d
,
h
e
n
c
e
,
t
h
e
C
T
X
o
f
E
C
G
w
a
s
u
n
a
f
f
e
c
t
e
d
b
y
t
h
e
p
r
e
s
e
n
c
e
o
f
t
h
e
a
n
t
i
o
x
i
d
a
n
t
s
,
N
-
a
c
e
t
y
l
c
y
s
t
e
i
n
e
a
n
d
g
l
u
t
a
t
h
i
o
n
e
,
a
n
d
c
a
t
a
l
a
s
e
.
T
h
e
C
T
X
o
f
E
C
G
w
a
s
u
n
a
f
f
e
c
t
e
d
b
y
a
m
e
t
a
b
o
l
i
c
a
c
t
i
v
a
t
i
n
g
s
y
s
t
e
m
,
i
.
e
.
a
h
e
p
a
t
i
c
m
i
c
r
o
s
o
m
a
l
S
-
9
m
i
x
.
E
C
G
i
n
d
u
c
e
d
a
p
o
p
t
o
s
i
s
i
n
t
h
e
c
a
r
c
i
n
o
m
a
H
S
C
-
2
c
e
l
l
s
,
b
u
t
n
o
t
i
n
t
h
e
n
o
r
m
a
l
H
G
F
-
2
f
i
b
r
o
b
l
a
s
t
s
P
r
o
s
t
a
t
e
D
U
1
4
5
E
C
G
C
h
u
n
g
e
t
a
l
.
(
4
)
E
G
C
G
,
E
G
C
a
n
d
E
C
G
b
u
t
n
o
t
E
C
s
u
p
p
r
e
s
s
t
h
e
g
r
o
w
t
h
a
n
d
i
n
d
u
c
e
a
p
o
p
t
o
s
i
s
i
n
h
u
m
a
n
p
r
o
s
t
a
t
e
c
a
n
c
e
r
D
U
1
4
5
c
e
l
l
s
l
a
r
g
e
l
y
t
h
r
o
u
g
h
a
n
i
n
c
r
e
a
s
e
i
n
r
e
a
c
t
i
v
e
o
x
y
g
e
n
s
p
e
c
i
e
s
(
R
O
S
)
f
o
r
m
a
t
i
o
n
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
d
e
p
o
l
a
r
i
z
a
t
i
o
n
.
T
h
e
g
r
o
w
t
h
s
u
p
p
r
e
s
s
i
o
n
,
a
p
o
p
t
o
s
i
s
i
n
d
u
c
t
i
o
n
,
R
O
S
f
o
r
m
a
t
i
o
n
a
n
d
m
i
t
o
c
h
o
n
d
r
i
a
l
d
e
p
o
l
a
r
i
z
a
t
i
o
n
a
r
e
i
n
a
s
i
m
i
l
a
r
o
r
d
e
r
,
i
.
e
.
E
C
G
>
E
G
C
G
>
E
G
C
>
E
C
.
E
G
C
G
d
i
d
n
o
t
a
l
t
e
r
t
h
e
e
x
p
r
e
s
s
i
o
n
o
f
B
C
L
-
2
,
B
C
L
-
X
(
L
)
a
n
d
B
A
D
i
n
D
U
1
4
5
c
e
l
l
s
F
i
b
r
o
s
a
r
c
o
m
a
H
T
1
0
8
0
E
C
G
M
a
e
d
a
-
Y
a
m
a
m
o
t
o
e
t
a
l
.
(
8
)
E
G
C
G
,
E
G
C
a
n
d
t
h
e
a
f
l
a
v
i
n
s
t
r
o
n
g
l
y
s
u
p
p
r
e
s
s
e
d
t
h
e
i
n
v
a
s
i
o
n
o
f
H
T
1
0
8
0
c
e
l
l
s
i
n
t
o
t
h
e
m
o
n
o
l
a
y
e
r
o
f
H
U
V
E
C
s
/
g
e
l
a
t
i
n
m
e
m
b
r
a
n
e
,
w
h
e
r
e
a
s
E
C
,
E
G
C
,
t
e
a
f
l
a
v
o
n
o
l
s
,
t
e
a
f
l
a
v
o
n
e
s
a
n
d
g
a
l
l
a
t
e
d
e
r
i
v
a
t
i
v
e
s
h
a
d
n
o
e
f
f
e
c
t
.
B
o
t
h
t
h
e
a
f
l
a
v
i
n
-
d
i
g
a
l
l
a
t
e
a
n
d
t
h
e
a
s
i
n
e
n
s
i
n
D
s
h
o
w
e
d
a
w
e
a
k
i
n
v
a
s
i
o
n
i
n
h
i
b
i
t
o
r
y
e
f
f
e
c
t
.
E
C
G
s
i
g
n
i
f
i
c
a
n
t
l
y
i
n
h
i
b
i
t
e
d
t
h
e
i
n
v
a
s
i
o
n
w
i
t
h
o
u
t
c
y
t
o
t
o
x
i
c
i
t
y
(
C
T
X
)
a
g
a
i
n
s
t
c
a
n
c
e
r
c
e
l
l
s
a
n
d
H
U
V
E
C
s
.
E
s
t
e
r
-
t
y
p
e
c
a
t
e
c
h
i
n
s
(
E
C
G
a
n
d
E
G
C
G
)
a
n
d
t
h
e
a
f
l
a
v
i
n
s
t
r
o
n
g
l
y
s
u
p
p
r
e
s
s
e
d
m
a
t
r
i
x
m
e
t
a
l
l
o
p
r
o
t
e
i
n
a
s
e
(
M
M
P
)
2
a
n
d
M
M
P
-
9
,
w
h
i
c
h
w
e
r
e
s
e
c
r
e
t
e
d
i
n
t
o
t
h
e
c
o
n
d
i
t
i
o
n
e
d
m
e
d
i
u
m
o
f
H
T
1
0
8
0
c
e
l
l
s
.
E
C
G
s
h
o
w
e
d
t
h
e
m
o
s
t
p
o
t
e
n
t
i
a
l
a
n
t
i
m
e
t
a
s
t
a
s
i
s
a
c
t
i
v
i
t
y
b
e
c
a
u
s
e
i
t
i
n
h
i
b
i
t
e
d
i
n
v
a
s
i
o
n
i
n
t
h
e
a
b
s
e
n
c
e
o
f
C
T
X
S
t
o
m
a
c
h
K
A
T
O
I
I
I
E
C
G
O
k
a
b
e
e
t
a
l
.
(
2
)
V
a
r
i
o
u
s
t
e
a
p
o
l
y
p
h
e
n
o
l
s
i
n
d
u
c
e
d
g
r
o
w
t
h
i
n
h
i
b
i
t
i
o
n
a
n
d
a
p
o
p
t
o
s
i
s
o
f
h
u
m
a
n
s
t
o
m
a
c
h
c
a
n
c
e
r
c
e
l
l
l
i
n
e
K
A
T
O
I
I
I
,
a
n
d
i
n
h
i
b
i
t
i
o
n
o
f
t
u
m
o
r
n
e
c
r
o
s
i
s
f
a
c
t
o
r
-
a
l
p
h
a
(
T
N
F
-
a
)
r
e
l
e
a
s
e
f
r
o
m
t
h
e
c
e
l
l
s
,
i
n
t
h
e
o
r
d
e
r
o
f
E
C
G
>
E
G
C
G
>
E
G
C
>
t
h
e
a
f
l
a
v
i
n
s
(
T
F
)
>
E
C
.
E
G
C
G
i
n
h
i
b
i
t
e
d
T
N
F
-
a
g
e
n
e
e
x
p
r
e
s
s
i
o
n
i
n
K
A
T
O
I
I
I
c
e
l
l
s
,
a
s
w
e
l
l
a
s
o
k
a
d
a
i
c
a
c
i
d
-
i
n
d
u
c
e
d
A
P
-
1
a
n
d
N
F
-
k
B
a
c
t
i
v
a
t
i
o
n
.
T
h
e
i
n
h
i
b
i
t
o
r
y
p
o
t
e
n
c
i
e
s
o
f
E
G
C
G
f
o
r
A
P
-
1
a
n
d
N
F
-
k
B
b
i
n
d
i
n
g
t
o
D
N
A
w
e
r
e
d
i
f
f
e
r
e
n
t
b
e
t
w
e
e
n
K
A
T
O
I
I
I
c
e
l
l
s
a
n
d
m
o
u
s
e
f
i
b
r
o
b
l
a
s
t
c
e
l
l
l
i
n
e
B
A
L
B
/
3
T
3
P
r
o
s
t
a
t
e
,
m
e
t
a
s
t
a
t
i
c
D
U
1
4
5
E
C
G
P
r
e
s
e
n
t
s
t
u
d
y
E
C
G
s
u
p
p
r
e
s
s
e
d
c
e
l
l
p
r
o
l
i
f
e
r
a
t
i
o
n
o
f
D
U
1
4
5
p
r
o
s
t
a
t
e
c
a
n
c
e
r
c
e
l
l
s
a
t
a
c
o
n
c
e
n
t
r
a
t
i
o
n
2
4
m
M
,
w
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eCAM 2006;3(2) 245time of CaP cell lines DU145 and HH870 and EOC line
HH450. No doubling was observed for HH639 cells treated
with ECG; instead cell number decreased, indicating cell
death. Table 1 summarizes the effects of EC, ECG, EGC and
EGCG on viability, doubling time and cycling of the four
cell lines. Untreated cells from each line reached confluency
in about 2.5 cell cycles. EC did not affect the proliferation of
DU145, HH870 or HH450 cells but it reduced the proliferation
of HH639 cells by half (P < 0.05) and prevented their conflu-
ent growth (Table 1). EGC did not affect the proliferation of
any cell line (Table 1), whereas EGCG arrested proliferation
of all four lines. ECG, followed by EGCG, was the most potent
inhibitor of cell growth and cycling.
Dosimetric Analysis of Growth to Tumor cells:
IC50 of ECG is Superior to EGCG
Proliferation of each cell line (n ¼ 3 per treatment) was
monitored with or without ECG or EGCG at concentrations
of 0, 25, 50, 75 and 100 mM. The dosimetric results plotted
in Fig. 6 shows concentration-dependent suppression of
cell growth by ECG and EGCG. The suppressive effect on
cell density was striking at higher concentrations of ECG
and EGCG. ECG was a more potent inhibitor of cell growth
than EGCG. At 25 mM of EGCG, cell numbers for HH870
and DU145 were significantly higher than control values.
Based on the results plotted in Fig. 6, IC50 values were
calculated. The IC50 values are 24–30 mM for ECG, versus
42–89 mM for EGCG (Table 2). ECG suppressed growth
at all higher concentrations tested (Fig. 6), whereas EGCG
significantly (P < 0.05) enhanced proliferation of CaP cells
at 25 mM, a finding relevant to chemoprevention trials with
EGCG only.
Discussion
Green tea is widely consumed in Japan and China and its poly-
phenolic components have a chemopreventive effect against
cancer in vitro and in vivo (39). A cup of green tea contains
100–150 mg catechins, of which 8% are EC, 15% are EGC,
15% are ECG and 50% are EGCG (40). Although numerous
investigations have shown the role of EGCG in cancer chemo-
prevention, only a few studies have attempted to compare the
relative antitumor efficacy of all four catechins (Table 3).
When we used a systematic approach to assess the effect of
various catechins on cell lines derived from gender-based can-
cers, we found that each catechin’s antitumor activity
depended on the type of tumor. EGCG was not always the
most potent chemopreventive agent.
Most of the earlier literature (Table 3) indicates that EGCG
is the most potent growth inhibitor of cell lines from glio-
blastoma, melanoma and cancers of the breast, colon, lung,
prostate (androgen-receptor-positive), pancreas, liver and
mouth. EGCG prevents proliferation of DU145 cells by arrest-
ing the cell cycle at G0/G1-phase (19). Gupta and others (26)
have documented that G0/G1-phase arrest is independent of
p53 mutation, and EGCG treatment of DU145 induces the cyc-
lin kinase inhibitor WAF1/p21. These observations suggest
that EGCG imposes a cell-cycle checkpoint (19). However,
our results showed that ECG may be more potent than
EGCG for inhibition of primary and metastatic CaP and EOC
cells (Fig. 4, Tables 1 and 2). ECG significantly reduced cell
proliferation (Table 1, Figs 2 and 3) and increased mean doub-
ling time (Table 1, Fig. 4).
The in vitro effect of chemopreventive agents can be studied
when tumor cells are in a matrix (1,4,27) or in a suspension
(28,29). We used the suspension method because it exposes
the entire cell surface to the chemotherapeutic agent. Our find-
ings confirm an earlier report that used the matrix method to
show that ECG is more potent than EGCG in suppressing the
proliferation of DU145 CaP cells (4). Thus reported differ-
ences in the relative efficacy of different catechins may not
be due to differences in methodology.
Not all tumor cells are killed by catechins. In our study, ECG
(50 mM) induced death of most but not all HH639 cells. Doub-
ling ECG’s IC50 concentration might increase the tumor kill
rate if ECG does not epimerize to CG. Our in vitro dose of
100 mM is equivalent to 29 mg (EC/EGC) to 45 mg (EGCG/
ECG), far less than the 100–150 mg (50% of which is
EGCG) in one cup of green tea. However, Lee et al. (41) repor-
ted that plasma levels of EGCG and EGC in healthy volunteers
increased to 78 and 223 ng ml
 1, respectively, 20 min after
drinking brewed green tea (1.2 g of tea solids in 200 ml hot
water). This suggests that drinking more than 10 cups of green
tea may be necessary to maintain a plasma concentration of
EGCG equivalent to that used in vitro by a dose of 50 mMo r
22.5 mg. Kaegi (42) suggested a daily intake of 13 cups of
green tea as a chemopreventive measure. Because this level
of tea consumption is impractically high, chemoprevention of
cancer with catechins may require administration of the appro-
priate catechin in a purified form.
In conclusion it may be stated that both green and black tea
polyphenols are important components of antitumor aspect of
complementary and alternative medicine (CAM), which play
a significant role in the American health care system and in
patients who suffer from chronic problems (43). While green
tea catechin gallates such as EGCG and ECG possess potent
antitumor activities, their epimers, commonly found in black
tea, act as potent inhibitor of proteases involved in replication
of viruses, including coronoviruses (44). There is a need to
understand preventive and therapeutic potential of catechin
gallates from both green and black teas. We are currently
designing a phase I chemopreventive study to examine the
effects of purified EGCG and ECG in patients who have been
chosen observational management of organ-confined prostate
cancer.
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